
Esperion is passionately committed to developing and commercializing convenient, complementary, consistent, oral LDL-C lowering therapies for patients with hypercholesterolemia and their physicians around the world. The bempedoic acid / ezetimibe combination pill and bempedoic acid are targeted, oral therapies that have been shown to significantly reduce elevated levels of LDL-C in patients inadequately treated with current lipid-modifying therapies. The Esperion-discovered and developed bempedoic acid-based therapies are “patient-friendly, physician-friendly, and payer-friendly”.
No one has added Esperion Therapeutics' vision statement yet.
Comparably data clearly shows that a focused mission statement and cohesive core company values are vital to maintaining employee alignment.